Breathe Well Live Well
|
Very poorly controlled asthma highly prevalent in TENOR II cohort after more than a decade
EurekAlert (press release) ATS 2016, SAN FRANCISCO — Nearly half (48%) of patients with severe or difficult-to-treat asthma in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens follow-up study (TENOR II) still had very poorly controlled (VPC) … |
View full post on asthma – Google News
A highly sensitive and selective impedimetric aptasensor for interleukin-17 receptor A.
Biosens Bioelectron. 2016 Feb 18;81:80-86
Authors: Jo H, Kim SK, Youn H, Lee H, Lee K, Jeong J, Mok J, Kim SH, Park HS, Ban C
Abstract
Interleukin-17 receptor A (IL-17RA) has been recognized as a valuable biomarker for diverse diseases, including autoimmune diseases. In this work, an electrochemical biosensor with great sensitivity and selectivity toward IL-17RA was fabricated using an IL-17RA aptamer (Kd=14.00nM) for the first time. The aptasensor was manufactured using electrodeposition of gold nanoparticles, and then quantitative detection of IL-17RA was performed based on impedimetry. The developed sensor exhibited a superior analytical performance for IL-17RA with a wide dynamic range of 10-10,000pg/mL in buffer and a detection limit of 2.13pg/mL, which is lower than that of commercially available ELISA kits. In addition, we validated the high specificity of the designed aptasensor to only IL-17RA, which showed good sensitivity even in human serum solution. Furthermore, the detection of the differentiated HL-60 cells expressing IL-17RA was successfully performed. Clinical applicability of the sensor was also demonstrated utilizing neutrophils separated from asthma patients. It is expected that the fabricated aptasensor will become an excellent diagnostic platform for IL-17RA-mediated diseases.
PMID: 26921556 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
Omalizumab Highly Effective in Reducing Severe Asthma Symptoms
Monthly Prescribing Reference (registration) Ivo Abraham, PhD, RN, from the University of Arizona in Tucson, and colleagues reviewed 24 real-life effectiveness studies of omalizumab in the treatment of severe allergic asthma. The studies included 4,117 unique patients from 32 countries … |
View full post on asthma – Google News
|
Omalizumab Highly Effective for Severe Allergic Asthma
Monthly Prescribing Reference (registration) Ivo Abraham, PhD, RN, from the University of Arizona in Tucson, and colleagues reviewed 24 real-life effectiveness studies of omalizumab in the treatment of severe allergic asthma. The studies included 4,117 unique patients from 32 countries … |
View full post on asthma – Google News
 NBCNews.com (blog) |
Asthma drug found highly effective in treating chronic, severe hives and itch
EurekAlert (press release) An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was … Asthma drug can ease agony of constant itch, too Asthma Drug Curbs Chronic Hives Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic … |
View full post on asthma – Google News
|
Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers
News-Medical.net Could it be that those with allergic rhinitis (hay fever) and childhood nasal allergies can finally get a break from their allergies and their allergy shots? Chicago's leading allergy, asthma, and immunology expert, Dr. Brian Rotskoff, who treats a … |
View full post on asthma – Google News
 ABC News |
9/11 Dust Cloud Highly Toxic
ABC News Research done at Mount Sinai in 2009 found that about eight percent of men and women who helped with rescue and recovery, or took part in other work at the site, reported asthma attacks. Normally, only about four percent of the population suffers from … |
View full post on asthma – Google News